|
|
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Sales are distributed geographically as follows: the United States (71.9%), Japan (3.7%), Germany (2.7%), Canada (2.4%), France (2.1%), Spain (1.4%), the United Kingdom (1.1%), Italy (1.1%), Netherlands (0.5%), Brazil (1.1%) and others (12%).
Number of employees : 30 000 people.
|
|
|
| 2019 | | USD (in Million) | % | | HUMIRA | 19,169 | 57.6% | | IMBRUVICA | 4,674 | 14.1% | | MAVYRET | 2,893 | 8.7% | | Creon | 1,041 | 3.1% | | Lupron | 887.00 | 2.7% | | VENCLEXTA | 792.00 | 2.4% | | Synthroid | 786.00 | 2.4% | | Synagis | 718.00 | 2.2% | | All Other | 511.00 | 1.5% | | Duodopa | 461.00 | 1.4% |
|
|
|
| 2019 | | USD (in Million) | % | | United States | 23,907 | 71.9% | | All Other Countries | 3,993 | 12% | | Japan | 1,211 | 3.6% | | Germany | 909.00 | 2.7% | | Canada | 813.00 | 2.4% | | France | 695.00 | 2.1% | | Spain | 472.00 | 1.4% | | United Kingdom | 372.00 | 1.1% | | Italy | 372.00 | 1.1% | | Brazil | 359.00 | 1.1% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
1,789,723,994 |
1,763,633,365 |
98.5% |
24,250,071 |
1.4% |
98.5% |
|
|
|
| Name | Equities | % | | The Vanguard Group, Inc. | 138,599,709 |
7.85% | | SSgA Funds Management, Inc. | 78,208,461 |
4.43% | | BlackRock Fund Advisors | 42,973,798 |
2.44% | | T. Rowe Price Associates, Inc. (Investment Management) | 41,778,780 |
2.37% | | Capital Research & Management Co. (Global Investors) | 40,804,113 |
2.31% | | Fidelity Management & Research Co. LLC | 28,180,247 |
1.60% | | Geode Capital Management LLC | 26,135,072 |
1.48% | | Northern Trust Investments, Inc.(Investment Management) | 24,153,136 |
1.37% | | JPMorgan Investment Management, Inc. | 19,163,242 |
1.09% | | Janus Capital Management LLC | 16,388,581 |
0.93% |
|
|
|
|
- - Main Market - S&P 100 / S&P 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50 |
|
|
|
|
| - Bloomberg Code : |
|
| - Reuters Code : |
ABBV.N |
| - Datastream Code : |
|
|
| Company contact information |
|
|
|
|
|
Berkshire's bet a bright spot in gloomy year for Big Pharma stocks |
Sector Pharmaceuticals - NEC
Connections : AbbVie Inc. |
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
